TDACW Translational Development Acquisition Corp.

Price Chart

Executive Summary

Translational Development Acquisition Corp. (TDAC) has entered into a definitive merger agreement to acquire Prologium Holding Inc., a solid-state battery developer, at a pre-money enterprise value of $3.8 billion. The transaction is expected to provide approximately $300 million in gross proceeds to Prologium's balance sheet through a combination of TDAC's trust cash and a PIPE investment, with a minimum cash condition of $250 million. The deal is structured as a two-step merger, with Prologium becoming the publicly listed entity, and is subject to shareholder approvals, SEC effectiveness of a registration statement, and other customary closing conditions.

Key Financial Metrics

Actionable Insight

Key Facts

• Pre-money enterprise value of Prologium is $3.8 billion, implying a pro forma enterprise value of approximately $3.88 billion.
• Targeting ~$300 million in gross proceeds from SPAC trust cash and PIPE investment, with a $250 million minimum cash condition.
• Prologium is a solid-state battery company with a gigafactory in Taoyuan, Taiwan (0.5 GWh capacity) and a planned gigafactory in Dunkirk, France (targeting 4 GWh by 2030E).
• Prologium has raised ~$690 million to date and has been awarded up to ~€1.4 billion in French government subsidies for the Dunkirk plant.
• The company holds over 1,000 patents as of YE 2025 and has shipped over 800,000 cells from its gigafactory since 2024.
• The transaction is expected to close in the second half of 2026, subject to shareholder approvals, SEC effectiveness, and other conditions.
• Post-closing, the board will consist of 9 directors, with one TDAC designee and three founder designees, including the founder.
• Existing Prologium shareholders will receive Company Class A, B, or C ordinary shares based on their holder category.
• TDAC warrants will be converted into Company warrants on the same terms.
• The company has a net cash position of $100 million as of the date of the agreement.

Financial Impact

Prologium valued at $3.8 billion pre-money enterprise value; targeting ~$300 million in gross proceeds; pro forma enterprise value ~$3.88 billion.

Risk Factors

• Shareholder redemptions could reduce available cash below the $250 million minimum cash condition, potentially scuttling the deal.
• PIPE investment may not fully materialize, impacting the balance sheet and growth plans.
• Execution risk in scaling manufacturing from 0.5 GWh to 4+ GWh in France, including construction delays or cost overruns.
• Competition from other solid-state and lithium-ion battery manufacturers could pressure market share and pricing.
• Regulatory and geopolitical risks, including tariffs and supply chain disruptions, could impact operations.
• The company is pre-revenue at scale; financial projections are management estimates and subject to significant uncertainty.

Market Snapshot

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

US Market Status

Related Tickers